Skip Navigation


European Heart Journal Advance Access originally published online on May 9, 2009
European Heart Journal 2009 30(14):1687-1689; doi:10.1093/eurheartj/ehp191
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/14/1687    most recent
ehp191v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rajan, L.
Right arrow Articles by Moliterno, D. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajan, L.
Right arrow Articles by Moliterno, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Options and outcomes with different antiplatelet strategies during primary percutaneous coronary intervention

Lawrence Rajan and David J. Moliterno*

Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY 40536, USA

* Corresponding author. Tel: +1 859 323 5843, Fax: +1 859 257 3537, Email: moliterno@uky.edu

This editorial refers to ‘Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality’{dagger}, by A. Witkowski et al., on page 1736

The first 10% of the full text of this article appears below.

The antithrombotic armamentarium for the treatment of acute coronary syndromes has expanded so rapidly over the past decade that this evolution has challenged the pace at which large-scale clinical trials can be completed for new indications and cardiac society guidelines can be updated. For example, there are presently 60 different antiplatelet and anticoagulant combinations for drugs with Class I or II indications for the treatment of ST-segment elevation myocardial infarction (STEMI). Considering clopidogrel in particular, the current European Society of Cardiology (ESC) guidelines1 recommend an oral loading dose of at least 300 mg for patients undergoing primary percutaneous coronary intervention (PCI) (Class I, Level of Evidence C). In the acute phase of STEMI, a clopidogrel maintenance dose of 75 mg daily is recommended (I, A) and, while the optimal duration of clopidogrel has not been determined, therapy for 12 months in all STEMI patients . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality
Adam Witkowski, Pawel Maciejewski, Wojciech Wasek, Lukasz A. Malek, Maciej Niewada, Bogumil Kaminski, Janusz Drzewiecki, Maciej Kosmider, Jacek Kubica, Witold Ruzyllo, Jan Z. Peruga, Dariusz Dudek, Grzegorz Opolski, Slawomir Dobrzycki, Robert J. Gil, and on behalf of the STEMI 2003 Registry Collaborators
EHJ 2009 30: 1736-1743. [Abstract] [Full Text]